How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse ...

Alert: Top Cash Back Card Now Offers 0% Intro APR Until Nearly 2027 Enjoy 0% intro APR on purchases and balance transfers for 15 months—plus up to 5% cash back in popular categories. Let's discuss ...

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...

Recursion Pharmaceuticals reported significant growth in sales and revenue for Q2 and the first half of 2025 but also experienced widening net losses. The release of their Boltz-2 model underscored a ...

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of Wednesday’s worst performers. Recursion Pharmaceuticals dropped for a third straight day on Wednesday, slashing 6.29 percent to close at $4.77 ...

Recursion Pharmaceuticals (NASDAQ: RXRX), a biotech company focused on artificial intelligence (AI), went public in April 2021. This was before ChatGPT, before AI became the hottest topic on Wall ...

The 2025 Florida Python Challenge yielded 294 Burmese pythons, the most since the challenge began. Taylor Stanberry won the Ultimate Grand Prize of $10,000 for capturing 60 pythons. Michael Marousky ...